The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a dearth of large-scale collections of patient-derived xenografts (PDXs) and paired tumoroids from metastatic disease, where experimental therapies are typically tested. Here we introduce XENTURION, an open-science resource offering a platform of 128 PDX models from patients with metastatic CRC, along with matched PDX-derived tumoroids. Multidimensional omics analyses indicate that tumoroids retain extensive molecular fidelity with parental PDXs. A tumoroid-based trial with the anti-EGFR antibody cetuximab reveals variable sensitivities that are consistent with clinical response biomarkers, mirror tumor growth changes in matched PDXs, and recapitulate EGFR genetic deletion outcomes. Inhibition of adaptive signals upregulated by EGFR blockade increases the magnitude of cetuximab response. These findings illustrate the potential of large living biobanks, providing avenues for molecularly informed preclinical research in oncology.

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients

Leto, Simonetta M.
Co-first
;
Grassi, Elena
Co-first
;
Avolio, Marco;Vurchio, Valentina;Cottino, Francesca;Ferri, Martina;Zanella, Eugenia R.;Borgato, Sofia;Corti, Giorgio;di Blasio, Laura;Somale, Desiana;Vara-Messler, Marianela;Galimi, Francesco;Sassi, Francesco;Lupo, Barbara;Catalano, Irene;Pinnelli, Marika;Viviani, Marco;Sperti, Luca;Mellano, Alfredo;Ferrero, Alessandro;Puliafito, Alberto;Primo, Luca;Bertotti, Andrea
Co-last
;
Trusolino, Livio
Co-last
2024-01-01

Abstract

The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a dearth of large-scale collections of patient-derived xenografts (PDXs) and paired tumoroids from metastatic disease, where experimental therapies are typically tested. Here we introduce XENTURION, an open-science resource offering a platform of 128 PDX models from patients with metastatic CRC, along with matched PDX-derived tumoroids. Multidimensional omics analyses indicate that tumoroids retain extensive molecular fidelity with parental PDXs. A tumoroid-based trial with the anti-EGFR antibody cetuximab reveals variable sensitivities that are consistent with clinical response biomarkers, mirror tumor growth changes in matched PDXs, and recapitulate EGFR genetic deletion outcomes. Inhibition of adaptive signals upregulated by EGFR blockade increases the magnitude of cetuximab response. These findings illustrate the potential of large living biobanks, providing avenues for molecularly informed preclinical research in oncology.
2024
15
7495
1
23
https://www.nature.com/articles/s41467-024-51909-2
Leto, Simonetta M.; Grassi, Elena; Avolio, Marco; Vurchio, Valentina; Cottino, Francesca; Ferri, Martina; Zanella, Eugenia R.; Borgato, Sofia; Corti, ...espandi
File in questo prodotto:
File Dimensione Formato  
s41467-024-51909-2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 2.83 MB
Formato Adobe PDF
2.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/2010170
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact